Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.

Offin M, Feldman D, Ni A, Myers ML, Lai WV, Pentsova E, Boire A, Daras M, Jordan EJ, Solit DB, Arcila ME, Jones DR, Isbell JM, Beal K, Young RJ, Rudin CM, Riely GJ, Drilon A, Tabar V, DeAngelis LM, Yu HA, Kris MG, Li BT.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32461. [Epub ahead of print]

PMID:
31469421
2.

Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.

Mondaca S, Offin M, Borsu L, Myers M, Josyula S, Makhnin A, Shen R, Riely GJ, Rudin CM, Ladanyi M, Yu HA, Li BT, Arcila ME.

Acta Oncol. 2019 Jul 26:1-6. doi: 10.1080/0284186X.2019.1645354. [Epub ahead of print]

PMID:
31347936
3.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.

Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D.

Clin Cancer Res. 2019 Jul 12. doi: 10.1158/1078-0432.CCR-19-0879. [Epub ahead of print]

PMID:
31300452
4.

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.

Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro A, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS.

Clin Cancer Res. 2019 Sep 15;25(18):5537-5547. doi: 10.1158/1078-0432.CCR-19-0032. Epub 2019 Jul 1.

PMID:
31263031
5.

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.

Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00386. Epub 2019 May 16. No abstract available.

6.

Efficacy of different analgesic or sedative drug therapies in pediatric patients with congenital heart disease undergoing surgery: a network meta-analysis.

Liu RZ, Li BT, Zhao GQ.

World J Pediatr. 2019 Jun;15(3):235-245. doi: 10.1007/s12519-019-00252-4. Epub 2019 Apr 23.

PMID:
31016566
7.

[Compound traditional Chinese medicine in treatment of diabetes].

Wu QH, Li BT, Tu J.

Zhongguo Zhong Yao Za Zhi. 2019 Mar;44(6):1104-1109. doi: 10.19540/j.cnki.cjcmm.20181212.001. Chinese.

PMID:
30989971
8.

Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.

Morikawa A, de Stanchina E, Pentsova E, Kemeny MM, Li BT, Tang K, Patil S, Fleisher M, Van Poznak C, Norton L, Seidman AD.

Clin Cancer Res. 2019 Jul 1;25(13):3784-3792. doi: 10.1158/1078-0432.CCR-18-3502. Epub 2019 Apr 15.

PMID:
30988080
9.

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, Zhao C, Hall MP, Hu Y, Sehnert AJ, Brown D, Ladanyi M, Rudin CM, Hunkapiller N, Feeney N, Mills GB, Paweletz CP, Janne PA, Solit DB, Riely GJ, Aravanis A, Oxnard GR.

Ann Oncol. 2019 Apr 1;30(4):597-603. doi: 10.1093/annonc/mdz046.

PMID:
30891595
10.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

PMID:
30755741
11.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT.

Eur J Cancer. 2019 Mar;109:28-35. doi: 10.1016/j.ejca.2018.11.030. Epub 2019 Jan 24.

PMID:
30685684
12.

Liquid biopsy guided precision therapy for lung cancers.

Xu C, Offin M, Paik PK, Li BT.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4173-S4175. doi: 10.21037/jtd.2018.11.02. No abstract available.

13.

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT.

J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. [Epub ahead of print]

PMID:
30496436
14.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

15.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

PMID:
30165371
16.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

PMID:
30068706
17.

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.

Liu D, Offin M, Harnicar S, Li BT, Drilon A.

Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252. doi: 10.2147/TCRM.S147381. eCollection 2018. Review.

18.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25.

PMID:
30045933
19.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):362.

20.

Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.

Mai HX, Mei GH, Zhao FL, Li BT, Tang YY, Zhang B, Xu XJ, Chen LJ.

J Cancer Res Ther. 2018 Jun;14(Supplement):S427-S432. doi: 10.4103/0973-1482.180609.

21.

[Progress on the treatment of terrible triad injury of elbow joint].

Yang WH, Tian XS, Li BT, Shang J.

Zhongguo Gu Shang. 2018 Jun 25;31(6):582-586. doi: 10.3969/j.issn.1003-0034.2018.06.019. Review. Chinese.

PMID:
29945418
22.

CT features of HER2-mutant lung adenocarcinomas.

Sawan P, Plodkowski AJ, Li AE, Li BT, Drilon A, Capanu M, Ginsberg MS.

Clin Imaging. 2018 Sep - Oct;51:279-283. doi: 10.1016/j.clinimag.2018.05.028. Epub 2018 Jun 7. Review.

23.

Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.

Isbell JM, Jones DR, Li BT.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2628-2631. doi: 10.1016/j.jtcvs.2017.12.157. Epub 2018 Mar 13. No abstract available. Erratum in: J Thorac Cardiovasc Surg. 2019 Aug 30;:.

PMID:
29615336
24.

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Mendzelevski B, Ferber G, Janku F, Li BT, Sullivan RJ, Welsch D, Chi W, Jackson J, Weng O, Sager PT.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1129-1141. doi: 10.1007/s00280-018-3564-1. Epub 2018 Mar 30.

25.

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.

Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M.

Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12.

26.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12.

27.

[Gegen Qinlian decoction activates PPARγ to ameliorate adipocytic insulin resistance in diabetic SD rats and IR-3T3-L1 adipocytes].

Luo XX, Zhu SL, Li BT, Shi XM, Tu J.

Zhongguo Zhong Yao Za Zhi. 2017 Dec;42(23):4641-4648. doi: 10.19540/j.cnki.cjcmm.20170928.003. Chinese.

PMID:
29376265
28.

Recombinant canine adenovirus type 2 expressing rabbit hemorrhagic disease virus VP60 protein provided protection against RHD in rabbits.

Jiang Q, Yu Z, Liu JS, Kong DS, Guo DC, Quan CS, Li BT, Hu XL, Qu L.

Vet Microbiol. 2018 Jan;213:15-20. doi: 10.1016/j.vetmic.2017.11.007. Epub 2017 Nov 6.

PMID:
29291998
29.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4. No abstract available.

30.

Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers.

Li BT, Stephens D, Chaft JE, Rudin CM, Jones DR, Rusch VW, Rimner A, Isbell JM.

Ann Transl Med. 2017 Dec;5(23):479. doi: 10.21037/atm.2017.09.02.

31.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

32.

Accelerating Discovery of Functional Mutant Alleles in Cancer.

Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, Sumer SO, Kundra R, Razavi P, Li BT, Reales DN, Socci ND, Jayakumaran G, Zehir A, Benayed R, Arcila ME, Chandarlapaty S, Ladanyi M, Schultz N, Baselga J, Berger MF, Rosen N, Solit DB, Hyman DM, Taylor BS.

Cancer Discov. 2018 Feb;8(2):174-183. doi: 10.1158/2159-8290.CD-17-0321. Epub 2017 Dec 15.

33.

Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer.

Lok BH, Ma J, Foster A, Perez CA, Shi W, Zhang Z, Li BT, Rudin CM, Rimner A, Wu AJ.

Adv Radiat Oncol. 2017 Aug 8;2(4):548-554. doi: 10.1016/j.adro.2017.08.001. eCollection 2017 Oct-Dec.

34.

TET1 inhibits cell proliferation by inducing RASSF5 expression.

Li BT, Yu C, Xu Y, Liu SB, Fan HY, Pan WW.

Oncotarget. 2017 Sep 23;8(49):86395-86409. doi: 10.18632/oncotarget.21189. eCollection 2017 Oct 17.

35.

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.

Yamamoto H, Toyooka S, Ninomiya T, Matsumoto S, Kanai M, Tomida S, Kiura K, Muto M, Suzawa K, Desmeules P, Kris MG, Li BT, Ladanyi M.

Oncologist. 2018 Feb;23(2):150-154. doi: 10.1634/theoncologist.2017-0345. Epub 2017 Nov 16.

36.

The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse.

Ji SY, Liu XM, Li BT, Zhang YL, Liu HB, Zhang YC, Chen ZJ, Liu J, Fan HY.

Mol Hum Reprod. 2017 Oct 1;23(10):698-707. doi: 10.1093/molehr/gax046.

PMID:
28961951
37.

Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.

Tan AC, Li BT, Nahar K, Danieletto S, Fong ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, Rutovitz JJ, McCloud P, Hughes TM, Marx GM.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e161-e166. doi: 10.1111/ajco.12779. Epub 2017 Sep 29.

PMID:
28960862
38.

CFP1 Regulates Histone H3K4 Trimethylation and Developmental Potential in Mouse Oocytes.

Yu C, Fan X, Sha QQ, Wang HH, Li BT, Dai XX, Shen L, Liu J, Wang L, Liu K, Tang F, Fan HY.

Cell Rep. 2017 Aug 1;20(5):1161-1172. doi: 10.1016/j.celrep.2017.07.011.

39.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.

Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.

40.

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.

Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N.

Cochrane Database Syst Rev. 2017 Jun 27;6:CD007047. doi: 10.1002/14651858.CD007047.pub2. Review.

41.

Relationship between catecholamine level and gene polymorphism of β1 adrenergic receptor G1165C in children with EV71 infection in hand foot and mouth disease.

Lei ZX, Li BT, Li HA, Li XM, Xie MF, Huang T, Wang Q, Wang YZ, Lin QY, Zhou LR, Feng NC, Li X, Zhu DM, Hai YP, Cui L, Zhang YQ, Liu ZW, Wu SY, Chen YZ, Zhu KQ, He XJ, Xiang W.

Asian Pac J Trop Med. 2017 May;10(5):473-477. doi: 10.1016/j.apjtm.2017.05.006. Epub 2017 May 18.

42.

[Relationship between NK Cell Reconstitution and aGVHD after Allo-HSCT].

Wan LL, Chen JL, Xu C, Li BT, Hu JW, Lou X, Yang F, Liu N, Su YF, Lan SC, Wang QH, Qiao ZQ, Wang L, Jiang M, Li YH, Hu LD.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):530-534. doi: 10.7534/j.issn.1009-2137.2017.02.040. Chinese.

PMID:
28446306
43.

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.

Offin M, Chabon JJ, Razavi P, Isbell JM, Rudin CM, Diehn M, Li BT.

J Oncol. 2017;2017:4517834. doi: 10.1155/2017/4517834. Epub 2017 Mar 14. Review.

44.

Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.

Wang YS, Li BT, Liu SX, Wen ZQ, Yang JH, Zhang HB, Hao XJ.

J Nat Prod. 2017 Apr 28;80(4):798-804. doi: 10.1021/acs.jnatprod.6b00391. Epub 2017 Apr 3.

PMID:
28368606
45.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, Baselga J, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ.

Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.

46.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

47.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

48.

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Selinger CI, Li BT, Pavlakis N, Links M, Gill AJ, Lee A, Clarke S, Tran TN, Lum T, Yip PY, Horvath L, Yu B, Kohonen-Corish MR, O'Toole SA, Cooper WA.

Histopathology. 2017 Feb;70(3):402-411. doi: 10.1111/his.13076. Epub 2016 Nov 15.

49.

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.

Eng J, Hsu M, Chaft JE, Kris MG, Arcila ME, Li BT.

Lung Cancer. 2016 Sep;99:53-6. doi: 10.1016/j.lungcan.2016.05.030. Epub 2016 May 31.

50.

Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Hellmann MD, Li BT, Chaft JE, Kris MG.

Ann Oncol. 2016 Oct;27(10):1829-35. doi: 10.1093/annonc/mdw271. Epub 2016 Jul 25. Review.

Supplemental Content

Support Center